{
"ranked_hypotheses": [
{
"rank": 1,
"title": "Pulsed TRPML1 Windowing Restores Flux",
"mechanism": "Low-dose, time-limited TRPML1 activation produces lysosomal Ca2+ microdomains that activate calcineurin-TFEB and fusion without depleting lysosomal Ca2+ reserve.",
"target_gene": "MCOLN1",
"confidence_score": 0.66,
"novelty_score": 0.72,
"feasibility_score": 0.62,
"impact_score": 0.76,
"composite_score": 0.70,
"testable_prediction": "A pulsed ML-SA1-like regimen will improve LC3 flux, p62 clearance, TFEB nuclear localization, and neuronal survival while preserving lysosomal Ca2+ and avoiding galectin-3 puncta.",
"skeptic_concern": "The same TFEB/fusion signal may become toxic if aged lysosomes cannot replenish Ca2+ or maintain pH."
},
{
"rank": 2,
"title": "Autophagy Priming Widens TRPML1 Safety Margin",
"mechanism": "Autophagy priming increases lysosomal demand and biogenesis capacity before TRPML1 agonism, converting channel activation from a depletion stress into a productive fusion and replenishment signal.",
"target_gene": "MCOLN1; ATG7; TFEB",
"confidence_score": 0.60,
"novelty_score": 0.70,
"feasibility_score": 0.58,
"impact_score": 0.72,
"composite_score": 0.66,
"testable_prediction": "Delayed autophagy priming followed by TRPML1 agonism will outperform simultaneous dosing and monotherapy in human neuron models with bafilomycin-controlled flux assays.",
"skeptic_concern": "Rapamycin and related primers have broad mTOR and metabolic effects, so synergy must be shown to be MCOLN1-dependent."
},
{
"rank": 3,
"title": "Mitophagy Context Determines TRPML1 Benefit",
"mechanism": "TRPML1 activation is beneficial when PINK1/Parkin mitophagy can deliver damaged mitochondria to lysosomes, but becomes less effective or harmful when mitochondrial quality-control input remains defective.",
"target_gene": "MCOLN1; PINK1; PARK2; LRRK2",
"confidence_score": 0.56,
"novelty_score": 0.76,
"feasibility_score": 0.54,
"impact_score": 0.70,
"composite_score": 0.64,
"testable_prediction": "TRPML1 agonism will show a wider therapeutic index in PINK1/Parkin-competent neurons than in PINK1/PARK2 loss-of-function or LRRK2-G2019S neurons unless combined with mitochondrial stress reduction.",
"skeptic_concern": "The interaction direction may invert by genotype, disease stage, and glial context."
}
],
"consensus_points": [
"TRPML1 is a plausible lysosomal target but should be developed as a windowed signalling intervention, not a simple chronic activator.",
"The decisive measurements are complete autophagic flux, lysosomal Ca2+ reserve, lysosomal membrane integrity, and neuronal survival.",
"Patient or model stratification by lysosomal and mitochondrial quality-control state is essential."
],
"dissent_points": [
"Theorist expects sequential priming to widen the window, while Skeptic argues rapamycin confounding and aged-lysosome fragility may erase the advantage.",
"The PINK1/Parkin interaction could define either a responsive subgroup or a subgroup where TRPML1 stimulation is insufficient."
],
"debate_summary": "The debate supports TRPML1 enhancement as scientifically valuable but only under a tightly measured exposure window. The strongest path is pulsed or sequential activation with explicit safety biomarkers for Ca2+ depletion, lysosomal membrane permeabilization, and failed flux."
}